Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry
- PMID: 35903705
- PMCID: PMC9314749
- DOI: 10.3389/fonc.2022.915028
Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry
Abstract
Background: Goblet cell adenocarcinoma (GCA) of the appendix is a rare and aggressive tumour with varying nomenclature and classification systems. This has led to heterogeneity in published data, and there is a lack of consensus on incidence, survival, and management.
Methods: We provide an overview of GCA with a comprehensive systematic review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology and a retrospective analysis of all cases recorded in the English National Cancer Registration and Analysis Service database between 1995 and 2018. The Kaplan-Meier estimator was used to calculate overall survival, and Cox proportional hazards regression was used to identify prognostic factors.
Results: The systematic review demonstrated an incidence of 0.05-0.3 per 100,000 per year among North American registry studies. The 1-, 3-, and 5-year survival rate was 95.5%, 85.9%-87.6%, and 76.0%-80.6%, respectively. Age, stage, and grade were identified as prognostic factors for survival. Our analysis included 1,225 cases. Age-standardised incidence was 0.0335 per year in 1995 and gradually rose to 0.158 per year in 2018. The 1-, 3-, and 5-year survival rate was 90.0% [95% confidence interval (95% CI): 85.4-94.0], 76.0% (95% CI: 73.8-80.9), and 68.6% (95% CI: 65.9-72.2), respectively. On univariate Cox regression analyses, female sex, stage, and grade were associated with worse overall survival. On multivariate analysis, only stage remained a statistically significant prognostic factor.
Conclusions: GCA of the appendix is rare, but incidence is increasing. We report a lower incidence and survival than North American registry studies. Higher stage was associated with decreased survival. Further prospective studies are required to establish optimal management.
Keywords: appendix tumour; goblet cell adenocarcinoma; goblet cell carcinoid; goblet cell carcinoma; mucin-secreting tumour.
Copyright © 2022 Palmer, Weerasuriya, Chandrakumaran, Rous, White, Paisey, Srirajaskanthan and Ramage.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?Surg Oncol. 2021 Mar;36:120-129. doi: 10.1016/j.suronc.2020.12.003. Epub 2020 Dec 10. Surg Oncol. 2021. PMID: 33360118
-
Treatment patterns and outcomes in goblet cell carcinoid tumors of the appendix.J Surg Oncol. 2019 Dec;120(7):1096-1101. doi: 10.1002/jso.25723. Epub 2019 Oct 8. J Surg Oncol. 2019. PMID: 31592538 Free PMC article.
-
[Clinicopathological characteristics of goblet cell adenocarcinoma of the appendix].Zhonghua Bing Li Xue Za Zhi. 2021 Jan 8;50(1):21-25. doi: 10.3760/cma.j.cn112151-20200324-00251. Zhonghua Bing Li Xue Za Zhi. 2021. PMID: 33396982 Chinese.
-
Goblet cell carcinoid of the appendix - diagnostic challenges and treatment updates: a case report and review of the literature.J Med Case Rep. 2018 Sep 24;12(1):275. doi: 10.1186/s13256-018-1789-6. J Med Case Rep. 2018. PMID: 30244681 Free PMC article. Review.
-
Controversies in appendiceal pathology: mucinous and goblet cell neoplasms.Pathology. 2022 Mar;54(2):167-176. doi: 10.1016/j.pathol.2021.09.003. Epub 2021 Nov 23. Pathology. 2022. PMID: 34836648 Review.
Cited by
-
Appendiceal Neuroendocrine Neoplasms: an Update for 2023.Curr Oncol Rep. 2024 Feb;26(2):114-120. doi: 10.1007/s11912-023-01484-4. Epub 2024 Jan 2. Curr Oncol Rep. 2024. PMID: 38168835 Review.
-
High-Grade Appendiceal Goblet Cell Adenocarcinoma-A Literature Review Starting from a Rare Case.Life (Basel). 2025 Jun 30;15(7):1047. doi: 10.3390/life15071047. Life (Basel). 2025. PMID: 40724549 Free PMC article. Review.
-
Gastric Amphicrine Carcinoma Showing Neuroendocrine and Pancreatic Acinar Cell Differentiation. Lesson from a Challenging Case Opening New Perspectives in the Diagnostic Work-Up of Gastric Neuroendocrine Neoplasms.Endocr Pathol. 2023 Sep;34(3):349-357. doi: 10.1007/s12022-023-09773-1. Epub 2023 May 30. Endocr Pathol. 2023. PMID: 37249796
-
Assessment of Treatment Response after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Appendiceal Peritoneal Metastases.Cancers (Basel). 2022 Oct 12;14(20):4998. doi: 10.3390/cancers14204998. Cancers (Basel). 2022. PMID: 36291781 Free PMC article.
-
Goblet cell adenocarcinoma: a case report and update regarding investigation and management.J Surg Case Rep. 2023 Apr 22;2023(4):rjad215. doi: 10.1093/jscr/rjad215. eCollection 2023 Apr. J Surg Case Rep. 2023. PMID: 37114082 Free PMC article.
References
-
- Brierley J, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. 8th ed. Chichester: Wiley; (2016).
LinkOut - more resources
Full Text Sources